23:03 , Nov 2, 2018 |  BioCentury  |  Finance

Innovent’s Hong Kong spark

A strong performance out of the gate for Innovent Biologics Inc. (HKSE:1801) reflects investor confidence in the company’s pipeline regardless of market conditions. The biologics company raised HK$3.3 billion ($421 million) in an IPO priced...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

Clearbridge BioMedics board of directors update

Clearbridge BioMedics , Singapore   Business: Diagnostic   Appointed: Chua Joo Hock, managing director and chief investment officer of Vertex Venture Management Pte. Ltd.; and Lu Yoh Chie, founder of Biosensors International Group Ltd. ,...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

BioFreedom regulatory update

Biosensors received CE Mark approval in the EU for its BioFreedom polymer-free, Biolimus A9-eluting stent. The company said it plans to launch the product in select markets this year, with a full commercial launch planned...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

Axxess drug eluting stent regulatory update

Devax received CE Mark approval in the EU for its Axxess biolimus A9-eluting stent to treat coronary bifurcations. Devax has rights to biolimus A9 from Biosensors International Group Ltd. (SGX:B20, Singapore). Devax Inc. , Lake...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Clinical News

Nobori regulatory update

Terumo received CE Mark approval for Nobori, a biolimus A9-eluting coronary stent, to treat restenosis. The company has exclusive marketing rights in Japan and non-exclusive rights in other countries, excluding the U.S., for the product...
01:34 , May 5, 2007 |  BC Extra  |  Financial News

Devax files for IPO

Devax (Lake Forest, Calif.) filed to raise up to $85 million in an IPO underwritten by Bear Stearns; Thomas Weisel Partners; CIBC World Markets; and AG Edwards . Devax's lead product is the Axxess stent...
07:00 , Jul 18, 2005 |  BC Week In Review  |  Clinical News

Axxion regulatory update

Biosensors received CE Mark approval for its Axxion, a polymer-free, paclitaxel-coated drug-eluting stent, to treat restenosis. The company is ready to launch Axxion in selected markets. Biosensors International Group Ltd. (SGX:B20), Hamilton, Bermuda   Product:...
08:00 , Nov 22, 2004 |  BC Week In Review  |  Clinical News

BioMatrix cardiovascular data

In the double-blind, German and Brazilian STEALTH trial in 120 patients, angiographic analysis at 6 months showed the BioMatrix group had a lower restenosis rate compared to the bare metal stent group (3.9% vs. 7.7%,...
08:00 , Nov 3, 2003 |  BC Week In Review  |  Company News

Biosensors International Pte Ltd., Terumo deal

Biosensors affiliate Occam International B.V. (Eindhoven, Holland) granted Terumo exclusive rights to sell in Japan the Occam Biolimus A-9-eluting stent to treat restenosis. Terumo also has non-exclusive rights to market the stent outside the U.S....
07:00 , Sep 22, 2003 |  BC Week In Review  |  Company News

Biosensors International Pte Ltd., X-Cell deal

Drug delivery company Biosensors and cardiovascular company X-Cell agreed in principle to merge, forming a drug-eluting stent company using anti-restenotic drug candidates. The new company would combine Biosensors' drug and polymer synthesis, stent designs and...